Pete Stavropoulos
Stock Analyst at Cantor Fitzgerald
(2.20)
# 2,824
Out of 5,135 analysts
53
Total ratings
30%
Success rate
3.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Pete Stavropoulos
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRVO CervoMed | Initiates: Overweight | n/a | $4.93 | - | 1 | Dec 18, 2025 | |
| NVAX Novavax | Initiates: Overweight | $18 | $8.69 | +107.13% | 1 | Oct 24, 2025 | |
| ALEC Alector | Downgrades: Neutral | n/a | $1.99 | - | 6 | Oct 22, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Neutral | n/a | $1.34 | - | 5 | Jul 7, 2025 | |
| DRUG Bright Minds Biosciences | Assumes: Overweight | n/a | $80.30 | - | 1 | Jul 2, 2025 | |
| VERA Vera Therapeutics | Maintains: Overweight | $107 → $100 | $44.07 | +126.91% | 8 | May 7, 2025 | |
| VYGR Voyager Therapeutics | Reiterates: Overweight | n/a | $3.34 | - | 2 | Mar 12, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Overweight | n/a | $7.51 | - | 6 | Mar 7, 2025 | |
| PLRX Pliant Therapeutics | Reinstates: Neutral | n/a | $1.25 | - | 5 | Mar 4, 2025 | |
| KALV KalVista Pharmaceuticals | Reiterates: Overweight | n/a | $15.45 | - | 1 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.06 | - | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.71 | - | 1 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $47.47 | - | 1 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $3.62 | +38.31% | 3 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $2.61 | +398.08% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $21.99 | -63.62% | 1 | Mar 20, 2023 |
CervoMed
Dec 18, 2025
Initiates: Overweight
Price Target: n/a
Current: $4.93
Upside: -
Novavax
Oct 24, 2025
Initiates: Overweight
Price Target: $18
Current: $8.69
Upside: +107.13%
Alector
Oct 22, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.99
Upside: -
Jasper Therapeutics
Jul 7, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.34
Upside: -
Bright Minds Biosciences
Jul 2, 2025
Assumes: Overweight
Price Target: n/a
Current: $80.30
Upside: -
Vera Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $107 → $100
Current: $44.07
Upside: +126.91%
Voyager Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.34
Upside: -
Arcturus Therapeutics Holdings
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $7.51
Upside: -
Pliant Therapeutics
Mar 4, 2025
Reinstates: Neutral
Price Target: n/a
Current: $1.25
Upside: -
KalVista Pharmaceuticals
Dec 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.45
Upside: -
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.06
Upside: -
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.71
Upside: -
Jun 27, 2024
Initiates: Overweight
Price Target: n/a
Current: $47.47
Upside: -
Sep 19, 2023
Reiterates: Overweight
Price Target: $5
Current: $3.62
Upside: +38.31%
Jul 17, 2023
Reiterates: Overweight
Price Target: $13
Current: $2.61
Upside: +398.08%
Mar 20, 2023
Reiterates: Overweight
Price Target: $8
Current: $21.99
Upside: -63.62%